BMXX.Y Stock Overview
Develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.51 |
| 52 Week High | €10.85 |
| 52 Week Low | €9.51 |
| Beta | 0.18 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| BMXX.Y | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.2% |
| 1Y | n/a | 5.5% | 25.6% |
Return vs Industry: Insufficient data to determine how BMXX.Y performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how BMXX.Y performed against the US Market.
Price Volatility
| BMXX.Y volatility | |
|---|---|
| BMXX.Y Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BMXX.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BMXX.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 12,846 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests.
bioMérieux S.A. Fundamentals Summary
| BMXX.Y fundamental statistics | |
|---|---|
| Market cap | US$11.89b |
| Earnings (TTM) | US$414.06m |
| Revenue (TTM) | US$3.97b |
28.7x
P/E Ratio3.0x
P/S RatioIs BMXX.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMXX.Y income statement (TTM) | |
|---|---|
| Revenue | €3.70b |
| Cost of Revenue | €1.63b |
| Gross Profit | €2.07b |
| Other Expenses | €1.68b |
| Earnings | €385.90m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.27 |
| Gross Margin | 55.93% |
| Net Profit Margin | 10.43% |
| Debt/Equity Ratio | 13.5% |
How did BMXX.Y perform over the long term?
See historical performance and comparison